Haemodynamic effects of riociguat in CTEPH and PAH: a 10-year observational study.
Suqiao YangYuan-Hua YangYixiao ZhangTuguang KuangJuanni GongJifeng LiYidan LiJianfeng WangXiaojuan GuoRan MiaoPublished in: ERJ open research (2021)
Riociguat improved PVR and cardiac index for up to 8 years, but not PAP. WHO FC may have certain predictive value for the long-term prognosis.